Peptide based P21RAS farnesyl transferase inhibitors : systematic modification of the tetrapeptide CA1A2X motif
- Author
- LEFTHERIS, K; KLINE, T; MEYERS, C. A; NATARAJAN, S; DEVIRGILIO, M. K; CHO, Y. H; PLUSCEC, J; RICCA, C; ROBINSON, S; SEIZINGER, B. R; MANNE, V
Bristol-Myers Squibb Pharmaceutical Research Institute, Princeton NJ 08540, United States - Source
Bioorganic & medicinal chemistry letters (Print). 1994, Vol 4, Num 7, pp 887-892 ; ref : 24 ref
- ISSN
- 0960-894X
- Scientific domain
- Biochemistry, molecular biology, biophysics; Pharmacology drugs
- Publisher
- Elsevier, Oxford
- Publication country
- United Kingdom
- Document type
- Article
- Language
- English
- Keyword (fr)
- Activité enzymatique Farnesyl-diphosphate farnesyltransferase Inhibiteur enzyme Modification Motif structural Peptide Substrat Tétrapeptide Enzyme Transferases
- Keyword (en)
- Enzymatic activity Farnesyl-diphosphate farnesyltransferase Enzyme inhibitor Modification Structural unit Peptides Substrate Tetrapeptide Enzyme Transferases
- Keyword (es)
- Actividad enzimática Farnesyl-diphosphate farnesyltransferase Inhibidor enzima Modificación Motivo estructural Péptido Substrato Tetrapéptido Enzima Transferases
- Classification
- Pascal
- 002 Biological and medical sciences / 002A Fundamental and applied biological sciences. Psychology / 002A02 Analytical, structural and metabolic biochemistry / 002A02E Enzymes and enzyme inhibitors / 002A02E03 Transferases
- Discipline
- Analytical, structural and metabolic biochemistry
- Origin
- Inist-CNRS
- Database
- PASCAL
- INIST identifier
- 3999215
Sauf mention contraire ci-dessus, le contenu de cette notice bibliographique peut être utilisé dans le cadre d’une licence CC BY 4.0 Inist-CNRS / Unless otherwise stated above, the content of this bibliographic record may be used under a CC BY 4.0 licence by Inist-CNRS / A menos que se haya señalado antes, el contenido de este registro bibliográfico puede ser utilizado al amparo de una licencia CC BY 4.0 Inist-CNRS
Access to the document
Install on your browser
DOI
10.1016/S0960-894X(01)80257-2 
https://dx.doi.org/10.1016/S0960-894X(01)80257-2
"O:13:\"PanistOpenUrl\":36:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000idc\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:29:\"10.1016\/S0960-894X(01)80257-2\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:111:\"Peptide based P21RAS farnesyl transferase inhibitors : systematic modification of the tetrapeptide CA1A2X motif\";s:9:\"\u0000*\u0000jtitle\";s:48:\"Bioorganic & medicinal chemistry letters (Print)\";s:9:\"\u0000*\u0000stitle\";s:32:\"Bioorg. med. chem. lett. (Print)\";s:7:\"\u0000*\u0000date\";s:4:\"1994\";s:9:\"\u0000*\u0000volume\";s:1:\"4\";s:8:\"\u0000*\u0000issue\";s:1:\"7\";s:8:\"\u0000*\u0000spage\";s:3:\"887\";s:8:\"\u0000*\u0000epage\";s:3:\"892\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0960-894X\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:9:\"LEFTHERIS\";s:10:\"\u0000*\u0000aufirst\";s:1:\"K\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:10:{i:0;s:8:\"KLINE, T\";i:1;s:12:\"MEYERS, C. A\";i:2;s:12:\"NATARAJAN, S\";i:3;s:16:\"DEVIRGILIO, M. K\";i:4;s:9:\"CHO, Y. H\";i:5;s:10:\"PLUSCEC, J\";i:6;s:8:\"RICCA, C\";i:7;s:11:\"ROBINSON, S\";i:8;s:15:\"SEIZINGER, B. R\";i:9;s:8:\"MANNE, V\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:111:\"Peptide based P21RAS farnesyl transferase inhibitors : systematic modification of the tetrapeptide CA1A2X motif\";s:8:\"\u0000*\u0000place\";s:6:\"Oxford\";s:6:\"\u0000*\u0000pub\";s:8:\"Elsevier\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:0:\"\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Panist access
"O:12:\"IstexOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:29:\"10.1016\/S0960-894X(01)80257-2\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:111:\"Peptide based P21RAS farnesyl transferase inhibitors : systematic modification of the tetrapeptide CA1A2X motif\";s:9:\"\u0000*\u0000jtitle\";s:48:\"Bioorganic & medicinal chemistry letters (Print)\";s:9:\"\u0000*\u0000stitle\";s:32:\"Bioorg. med. chem. lett. (Print)\";s:7:\"\u0000*\u0000date\";s:4:\"1994\";s:9:\"\u0000*\u0000volume\";s:1:\"4\";s:8:\"\u0000*\u0000issue\";s:1:\"7\";s:8:\"\u0000*\u0000spage\";s:3:\"887\";s:8:\"\u0000*\u0000epage\";s:3:\"892\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0960-894X\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:9:\"LEFTHERIS\";s:10:\"\u0000*\u0000aufirst\";s:1:\"K\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:10:{i:0;s:8:\"KLINE, T\";i:1;s:12:\"MEYERS, C. A\";i:2;s:12:\"NATARAJAN, S\";i:3;s:16:\"DEVIRGILIO, M. K\";i:4;s:9:\"CHO, Y. H\";i:5;s:10:\"PLUSCEC, J\";i:6;s:8:\"RICCA, C\";i:7;s:11:\"ROBINSON, S\";i:8;s:15:\"SEIZINGER, B. R\";i:9;s:8:\"MANNE, V\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:111:\"Peptide based P21RAS farnesyl transferase inhibitors : systematic modification of the tetrapeptide CA1A2X motif\";s:8:\"\u0000*\u0000place\";s:6:\"Oxford\";s:6:\"\u0000*\u0000pub\";s:8:\"Elsevier\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:0:\"\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Istex access
"O:16:\"UnpaywallOpenUrl\":35:{s:8:\"\u0000*\u0000email\";s:27:\"assistance-portail@inist.fr\";s:6:\"\u0000*\u0000fmt\";N;s:6:\"\u0000*\u0000doi\";s:29:\"10.1016\/S0960-894X(01)80257-2\";s:6:\"\u0000*\u0000pii\";N;s:7:\"\u0000*\u0000pmid\";N;s:9:\"\u0000*\u0000atitle\";N;s:9:\"\u0000*\u0000jtitle\";N;s:9:\"\u0000*\u0000stitle\";N;s:7:\"\u0000*\u0000date\";N;s:9:\"\u0000*\u0000volume\";N;s:8:\"\u0000*\u0000issue\";N;s:8:\"\u0000*\u0000spage\";N;s:8:\"\u0000*\u0000epage\";N;s:8:\"\u0000*\u0000pages\";N;s:7:\"\u0000*\u0000issn\";N;s:8:\"\u0000*\u0000eissn\";N;s:9:\"\u0000*\u0000aulast\";N;s:10:\"\u0000*\u0000aufirst\";N;s:9:\"\u0000*\u0000auinit\";N;s:10:\"\u0000*\u0000auinitm\";N;s:5:\"\u0000*\u0000au\";N;s:9:\"\u0000*\u0000aucorp\";N;s:7:\"\u0000*\u0000isbn\";N;s:8:\"\u0000*\u0000coden\";N;s:8:\"\u0000*\u0000genre\";N;s:7:\"\u0000*\u0000part\";N;s:9:\"\u0000*\u0000btitle\";N;s:8:\"\u0000*\u0000title\";N;s:8:\"\u0000*\u0000place\";N;s:6:\"\u0000*\u0000pub\";N;s:10:\"\u0000*\u0000edition\";N;s:9:\"\u0000*\u0000tpages\";N;s:9:\"\u0000*\u0000series\";N;s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";N;}"
Unpaywall access
"O:16:\"EuropePMCOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:29:\"10.1016\/S0960-894X(01)80257-2\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:111:\"Peptide based P21RAS farnesyl transferase inhibitors : systematic modification of the tetrapeptide CA1A2X motif\";s:9:\"\u0000*\u0000jtitle\";s:48:\"Bioorganic & medicinal chemistry letters (Print)\";s:9:\"\u0000*\u0000stitle\";s:32:\"Bioorg. med. chem. lett. (Print)\";s:7:\"\u0000*\u0000date\";s:4:\"1994\";s:9:\"\u0000*\u0000volume\";s:1:\"4\";s:8:\"\u0000*\u0000issue\";s:1:\"7\";s:8:\"\u0000*\u0000spage\";s:3:\"887\";s:8:\"\u0000*\u0000epage\";s:3:\"892\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0960-894X\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:9:\"LEFTHERIS\";s:10:\"\u0000*\u0000aufirst\";s:1:\"K\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:10:{i:0;s:8:\"KLINE, T\";i:1;s:12:\"MEYERS, C. A\";i:2;s:12:\"NATARAJAN, S\";i:3;s:16:\"DEVIRGILIO, M. K\";i:4;s:9:\"CHO, Y. H\";i:5;s:10:\"PLUSCEC, J\";i:6;s:8:\"RICCA, C\";i:7;s:11:\"ROBINSON, S\";i:8;s:15:\"SEIZINGER, B. R\";i:9;s:8:\"MANNE, V\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:111:\"Peptide based P21RAS farnesyl transferase inhibitors : systematic modification of the tetrapeptide CA1A2X motif\";s:8:\"\u0000*\u0000place\";s:6:\"Oxford\";s:6:\"\u0000*\u0000pub\";s:8:\"Elsevier\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:0:\"\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Europe PubMed Central access
"O:11:\"BaseOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:29:\"10.1016\/S0960-894X(01)80257-2\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:111:\"Peptide based P21RAS farnesyl transferase inhibitors : systematic modification of the tetrapeptide CA1A2X motif\";s:9:\"\u0000*\u0000jtitle\";s:48:\"Bioorganic & medicinal chemistry letters (Print)\";s:9:\"\u0000*\u0000stitle\";s:32:\"Bioorg. med. chem. lett. (Print)\";s:7:\"\u0000*\u0000date\";s:4:\"1994\";s:9:\"\u0000*\u0000volume\";s:1:\"4\";s:8:\"\u0000*\u0000issue\";s:1:\"7\";s:8:\"\u0000*\u0000spage\";s:3:\"887\";s:8:\"\u0000*\u0000epage\";s:3:\"892\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0960-894X\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:9:\"LEFTHERIS\";s:10:\"\u0000*\u0000aufirst\";s:1:\"K\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:10:{i:0;s:8:\"KLINE, T\";i:1;s:12:\"MEYERS, C. A\";i:2;s:12:\"NATARAJAN, S\";i:3;s:16:\"DEVIRGILIO, M. K\";i:4;s:9:\"CHO, Y. H\";i:5;s:10:\"PLUSCEC, J\";i:6;s:8:\"RICCA, C\";i:7;s:11:\"ROBINSON, S\";i:8;s:15:\"SEIZINGER, B. R\";i:9;s:8:\"MANNE, V\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:111:\"Peptide based P21RAS farnesyl transferase inhibitors : systematic modification of the tetrapeptide CA1A2X motif\";s:8:\"\u0000*\u0000place\";s:6:\"Oxford\";s:6:\"\u0000*\u0000pub\";s:8:\"Elsevier\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:0:\"\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Base Search access
"O:12:\"ArXivOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:29:\"10.1016\/S0960-894X(01)80257-2\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:111:\"Peptide based P21RAS farnesyl transferase inhibitors : systematic modification of the tetrapeptide CA1A2X motif\";s:9:\"\u0000*\u0000jtitle\";s:48:\"Bioorganic & medicinal chemistry letters (Print)\";s:9:\"\u0000*\u0000stitle\";s:32:\"Bioorg. med. chem. lett. (Print)\";s:7:\"\u0000*\u0000date\";s:4:\"1994\";s:9:\"\u0000*\u0000volume\";s:1:\"4\";s:8:\"\u0000*\u0000issue\";s:1:\"7\";s:8:\"\u0000*\u0000spage\";s:3:\"887\";s:8:\"\u0000*\u0000epage\";s:3:\"892\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0960-894X\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:9:\"LEFTHERIS\";s:10:\"\u0000*\u0000aufirst\";s:1:\"K\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:10:{i:0;s:8:\"KLINE, T\";i:1;s:12:\"MEYERS, C. A\";i:2;s:12:\"NATARAJAN, S\";i:3;s:16:\"DEVIRGILIO, M. K\";i:4;s:9:\"CHO, Y. H\";i:5;s:10:\"PLUSCEC, J\";i:6;s:8:\"RICCA, C\";i:7;s:11:\"ROBINSON, S\";i:8;s:15:\"SEIZINGER, B. R\";i:9;s:8:\"MANNE, V\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:111:\"Peptide based P21RAS farnesyl transferase inhibitors : systematic modification of the tetrapeptide CA1A2X motif\";s:8:\"\u0000*\u0000place\";s:6:\"Oxford\";s:6:\"\u0000*\u0000pub\";s:8:\"Elsevier\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:0:\"\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
arXiv access
